MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas

MLA

Hideaki Abe, et al. “MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas.” Frontiers in Oncology, vol. 9, Jan. 2020. EBSCOhost, https://doi.org/10.3389/fonc.2019.01568.

APA

Hideaki Abe, Manabu Natsumeda, Masayasu Okada, Jun Watanabe, Yoshihiro Tsukamoto, Yu Kanemaru, Junichi Yoshimura, Makoto Oishi, Rintaro Hashizume, Akiyoshi Kakita, & Yukihiko Fujii. (2020). MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas. Frontiers in Oncology, 9. https://doi.org/10.3389/fonc.2019.01568

Chicago

Hideaki Abe, Manabu Natsumeda, Masayasu Okada, Jun Watanabe, Yoshihiro Tsukamoto, Yu Kanemaru, Junichi Yoshimura, et al. 2020. “MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas.” Frontiers in Oncology 9 (January). doi:10.3389/fonc.2019.01568.